This project concentrates on assisting the design and development of ribonuclease (RNase) H inhibitors (RNHIs) using a combination of X-ray crystallography (Arnold) and computational modeling (Levy). The central aims of the proposed work are (i) to determine the structures of HIV-1 RT with a series of novel RNHIs being pursued by scientists at Millenia Hope Inc. as leads on the path to developing a first-in-class therapeutic agent for the treatment of AIDS;ii) to develop and apply computational methodologies to both high-resolution conformational analysis and refinement of structures determined as well as to assist in iterative improvement of lead compounds with favorable antiviral activity that bind to this site;(iii) to determine the structures of HIV-1 RT with derivatives with improved activity that result from program activity; and iv) to provide structural and computational support to other program components (Parniak and Baroudy) to assist in the interpretation and design of biochemical, biophysical, and genetic studies of the most promising molecules. The project will involve a close collaboration among the teams of Eddy Arnold and Ronald Levy at Rutgers University, Michael Parniak at University of Pittsburgh, and Bahige Baroudy at Millenia Hope Inc. HIV reverse transcriptase (RT) is the target for many clinically important anti-AIDS drugs. Both nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs) are effective for AIDS treatment, but their efficacy is limited by the emergence of drug-resistant viral variants that affect one or both binding sites. The RNase H activity of HIV RT is essential for HIV replication. Because the anticipated binding site(s) for the RNHIs under study are expected to be distinct from the NRTI- and NNRTI-binding sites, new RNHIs that will be developed by the program should have little or no cross-resistance with the existing NRTI and NNRTI families of antivirals, thus providing opportunities for novel therapeutic strategies in the treatment of AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI073975-03
Application #
7770857
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
3
Fiscal Year
2009
Total Cost
$438,323
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Himmel, Daniel M; Myshakina, Nataliya S; Ilina, Tatiana et al. (2014) Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs. J Mol Biol 426:2617-31
Christen, Martin T; Menon, Lakshmi; Myshakina, Nataliya S et al. (2012) Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. Chem Biol Drug Des 80:706-16
Kirby, Karen A; Marchand, Bruno; Ong, Yee Tsuey et al. (2012) Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob Agents Chemother 56:2048-61
Ilina, Tatiana; Labarge, Krystal; Sarafianos, Stefan G et al. (2012) Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Biology (Basel) 1:521-41
Gong, Qingguo; Menon, Lakshmi; Ilina, Tatiana et al. (2011) Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem Biol Drug Des 77:39-47
Davis, Caroline A; Parniak, Michael A; Hughes, Stephen H (2011) The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC. Virology 419:64-71
Felts, Anthony K; Labarge, Krystal; Bauman, Joseph D et al. (2011) Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model 51:1986-98
Abram, Michael E; Sarafianos, Stefan G; Parniak, Michael A (2010) The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site. Retrovirology 7:6
Sarafianos, Stefan G; Marchand, Bruno; Das, Kalyan et al. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 385:693-713